Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
Open Access
- 29 April 2023
- journal article
- review article
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 13 (4) , 701-711
Abstract
Prostate-specific membrane antigen (PSMA) represents a promising target for PSMA-overexpressing diseases, especially prostate cancer-a common type of cancer among men worldwide. In response to the challenges in tackling prostate cancers, several promising PSMA inhibitors from a variety of molecular scaffolds (e.g., phosphorous-, thiol-, and urea-based molecules) have been developed. In addition, PSMA inhibitors bearing macrocyclic chelators have attracted interest due to their favorable pharmacokinetic properties. Recently, conjugating a small PSMA molecule inhibitor-bearing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator, as exemplified by [177Lu]Lu-PSMA-617 could serve as a molecular imaging probe and targeted radioligand therapy (TRT) of metastatic castration resistant prostate cancer (mCRPC). Hence, studies related to mCRPC have drawn global attention. In this review, the recent development of PSMA ligand-617-labeled with 177Lu for the management of mCRPC is presented. Its molecular mechanism of action, safety, efficacy, and future direction are also described.Keywords
This publication has 99 references indexed in Scilit:
- Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate CancerFrontiers in Oncology, 2013
- Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigenBioorganic & Medicinal Chemistry Letters, 2011
- Imaging techniques for prostate cancer: implications for focal therapyNature Reviews Urology, 2009
- A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate CancerJournal of Medicinal Chemistry, 2008
- Prostate cancerThe Lancet, 2008
- Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancerCancer Treatment Reviews, 2008
- Prostate-Specific Membrane Antigen Regulates Angiogenesis by Modulating Integrin Signal TransductionMolecular and Cellular Biology, 2006
- Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate CancerJournal of Clinical Oncology, 2005
- Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancerJournal of Cellular Biochemistry, 2003
- Design of Remarkably Simple, Yet Potent Urea-Based Inhibitors of Glutamate Carboxypeptidase II (NAALADase)Journal of Medicinal Chemistry, 2001